Interestingly, in a biological setting of impaired humoral response (hematological malignancies), CD8 T cells have been shown to compensate for impaired humoral immunity in Covid-19 patients (38), presenting a possible mechanism by which the KTx patients have an altered B cell response while still retaining the higher frequency CD8 effector and CD8 TSCM subsets. Here, CD8A is linked to hematologic disorder.